Antibacterial Drug Development in Multidrug-Resistant Infections

The global rise of multidrug-resistant bacterial pathogens has rendered many conventional antibiotics ineffective, fuelling urgent efforts to replenish and diversify the antibacterial pipeline. Current strategies encompass both traditional small-molecule discovery and nontraditional approaches such as antimicrobial peptides, antibody–antibiotic conjugates and adjuvant therapy. Central to these efforts is the identification of novel pharmacophores, alongside optimisation of existing scaffolds to overcome resistance mechanisms. Iron-chelating siderophore–antibiotic conjugates exemplify the “Trojan horse” concept, exploiting bacterial iron uptake pathways to enhance intracellular drug delivery. Peptide‐based agents offer a complementary avenue, often exhibiting broad-spectrum activity and a low propensity for resistance development. In tandem, adjuvant compounds that inhibit resistance enzymes or disrupt biofilms seek to rejuvenate the efficacy of legacy drugs. Robust preclinical evaluation now embraces physiologically relevant media and animal models to predict in vivo performance more accurately. Meanwhile, innovative clinical trial designs—including adaptive and hierarchical endpoints—are streamlining proof-of-concept studies in severely ill populations. Collective efforts by industry, academia and regulatory bodies aim to fast-track candidates while ensuring safety and maintaining rigorous efficacy standards. Despite these advances, critical gaps remain in late-stage development, particularly against priority Gram-negative pathogens. Sustained investment, coupled with global stewardship and equitable access initiatives, will be essential to translate laboratory breakthroughs into clinical impact and curb the spread of untreatable infections.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antibacterial Drug Development in Multidrug-Resistant Infections publication trend

The graph below shows the total number of articles in antibacterial drug development in multidrug-resistant infections across all publications each year (not limited to Nature Index journals).

Technical terms

Multidrug-resistant (MDR): Bacteria non-susceptible to multiple antibiotic classes, often due to combined resistance mechanisms.

Pharmacophore: The set of structural features within a molecule necessary to ensure optimal interactions with a specific biological target.

Siderophore: A low-molecular-weight compound secreted by bacteria to chelate iron, sometimes harnessed to facilitate antibiotic entry.

Minimum inhibitory concentration (MIC): The lowest concentration of an antimicrobial agent required to prevent visible growth of a microorganism under defined conditions.

References

1. Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. Antimicrobial Agents and Chemotherapy (2022).
2. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE’s STAT-Net. Intensive Care Medicine (2017).
3. Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy (2021).
4. In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii. Antibiotics (2022).